Less Is More: FDA May Narrow Risk Info In Rx Drug TV Ads
Executive Summary
Agency is considering whether drug broadcast ads should note only risks that are severe, serious or actionable; FDA study finds this limitation improves risk recall and recognition of benefits.
You may also be interested in...
Bill Would Make US FDA Issue Final Rule On Risk Information In Broadcast DTC Ads
Proposed rule issued in March 2010 requires ‘major statement’ on a drug’s side effects in ‘a clear, conspicuous, and neutral manner’ for TV and radio ads. Bill would mandate a final rule within six months.
Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information
Upcoming research projects will look at presentation of FDA approval status, timing of disease awareness ads, and healthcare professional views.
Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017
Last year's record low five letters came as FDA launched flurry of studies on DTC, professional ads; 'Bad Ad' complaints totaled more than 100.